Axxam and Proximagen enter into a strategic collaboration for the discovery of novel molecules against targets for CNS disorders, pain and inflammation

January 10th 2018 – Milan (Italy) and Cambridge (UK) Axxam S.p.A. and Proximagen Ltd. today announced a strategic drug discovery collaboration for the identification and…

Read More

Midazolam Nasal Spray (USL261) Phase 3 Trial Meets Primary Efficacy Endpoint In Patients With Seizure Clusters

Cambridge, UK – April 26, 2017 Proximagen Limited (Proximagen) today announced that its pivotal Phase 3 trial of intranasal midazolam (USL261) for the rescue treatment…

Read More

Proximagen to Become Wholly-Owned Subsidiary of ACOVA

Cambridge, UK – April 20, 2017 Proximagen’s parent company Upsher-Smith Laboratories, Inc. (Upsher-Smith), a business owned by the Evenstad family, today announced an agreement to…

Read More


BioTrinity (UK) (23-25 April 2018)


Read More

Bio Europe (12-14 March 2018)


Read More